FGD3

Across TCGA pan-cancer cohorts, FGD3 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of FGD3’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where FGD3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types FGD3 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD, LSCC, and CCRCC are the cancer types where FGD3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FGD3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−0.595	<.001	9	view →
LSCC	Male	All	−0.369	<.001	7	view →
CCRCC	Male	All	−0.203	<.001	7	view →
HNSC	All	All	+0.237	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

FGD3–LUAD

Open the LUAD breakdown →